ROCKAWAY, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s CEO, Dan Goldberger, is scheduled to participate in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference August 12 - 13, 2024. Please contact Needham to schedule a 1x1 meeting.
In addition, Brian Posner, CFO of electroCore, Inc. is scheduled to attend the 44th Annual Canaccord Genuity Growth Conference taking place at InterContinental Hotel in Boston, MA. electroCore will host 1x1 investor meetings on August 13, 2024. Please contact Canaccord Genuity to schedule a 1x1 meeting.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.11 |
| Daily Change: | 0.11 1.83 |
| Daily Volume: | 9,026 |
| Market Cap: | US$39.410M |
September 10, 2024 August 07, 2024 August 01, 2024 June 25, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
